Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Injectable TQD3606 in a Single Center, Randomized, Double-blind, Placebo-controlled, Single, Multiple Dosing in Healthy Subjects, and to Explore Urinary Excretion of the Product
Latest Information Update: 04 Apr 2024
At a glance
- Drugs Avibactam/meropenem (Primary) ; Avibactam; Meropenem
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 04 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 28 Apr 2022 New trial record